NeuroNova 1

Alternative Names: CLD-101; NeuroNova-1; NNV-1

Latest Information Update: 20 Mar 2024

Price : $50 ^*

Adis is an information provider. We do not sell or distribute actual drugs.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

Originator Northwestern University
Developer Calidi Biotherapeutics; City of Hope National Medical Center; Northwestern University
Class Antineoplastics; Gene therapies; Immunotherapies; Oncolytic viruses; Stem cell therapies
Mechanism of Action Cell death stimulants; Immunologic cytotoxicity

Orphan Drug Status

Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

No
New Molecular Entity No

20 Mar 2024 neuroNova 1 is still in preclinical trials for Ovarian canecr in USA
11 Mar 2024 Calidi Biotherapeutics plans a clinical trial for Ovarian cancer (Metastatic disease, Second-line therapy or greater)
20 Nov 2023 Calidi Biotherapeutics plans a phase Ib/II trial for Glioblastoma (Newly diagnosed) in the first half of 2024

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com